Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ABIO

ABIO - ARCA biopharma Inc Stock Price, Fair Value and News

1.67USD+0.02 (+1.21%)Market Closed
Watchlist

Market Summary

USD1.67+0.02
Market Closed
1.21%

ABIO Stock Price

View Fullscreen

ABIO RSI Chart

ABIO Valuation

Market Cap

24.2M

Price/Earnings (Trailing)

-4.54

Price/Sales (Trailing)

12.37

EV/EBITDA

0.74

Price/Free Cashflow

-4.83

ABIO Price/Sales (Trailing)

ABIO Profitability

EBT Margin

-987.33%

Return on Equity

-14.42%

Return on Assets

-14.1%

Free Cashflow Yield

-20.7%

ABIO Fundamentals

ABIO Revenue

Revenue (TTM)

2.0M

Rev. Growth (Yr)

33.96%

Rev. Growth (Qtr)

-2.34%

ABIO Earnings

Earnings (TTM)

-5.3M

Earnings Growth (Yr)

7.24%

Earnings Growth (Qtr)

23.53%

Breaking Down ABIO Revenue

Last 7 days

0.6%

Last 30 days

2.5%

Last 90 days

-7.7%

Trailing 12 Months

-18.5%

How does ABIO drawdown profile look like?

ABIO Financial Health

Current Ratio

59.01

ABIO Investor Care

Shares Dilution (1Y)

0.63%

Diluted EPS (TTM)

-0.37

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023995.5K1.3M1.6M2.0M
2022178.5K344.0K509.5K675.0K
20216.0K7.0K10.0K13.0K
2020158.0K112.0K63.0K28.0K
2019159.0K164.0K174.0K172.0K
2018163.0K167.0K163.0K162.0K
2017193.0K185.0K176.0K167.0K
201634.0K79.0K128.0K169.0K
20156.0K6.0K8.0K14.0K
20147.0K8.0K8.0K7.0K
20132.8K3.5K4.3K5.0K
20122.0K2.0K2.0K2.0K
2011572.8K382.5K192.3K2.0K
2010000763.0K

Tracking the Latest Insider Buys and Sells of ARCA biopharma Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 16, 2022
funicular funds, lp
acquired
3,550,000
2.5
1,420,000
-
Dec 08, 2022
dekker c. jeffrey
acquired
-
-
40,000
chief financial officer
Dec 08, 2022
keuer thomas a
acquired
-
-
40,000
chief operating officer
Jul 01, 2022
funicular funds, lp
sold
-
-
-2,580,450
-
Jul 01, 2022
funicular funds, lp
acquired
-
-
2,580,450
-
May 25, 2022
funicular fund, lp
bought
150,740
2.3244
64,851
-
May 24, 2022
funicular fund, lp
bought
41,383
2.2851
18,110
-
May 23, 2022
funicular fund, lp
bought
5,280
2.295
2,301
-
May 19, 2022
funicular fund, lp
bought
2.25
2.25
1.00
-
May 18, 2022
funicular fund, lp
bought
30,125
2.3046
13,072
-

1–10 of 38

Which funds bought or sold ABIO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 20, 2024
Cable Car Capital LLC
new
-
6,800,770
6,800,770
7.06%
Feb 14, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC
sold off
-100
-94,365
-
-%
Feb 14, 2024
CITADEL ADVISORS LLC
new
-
10,744
10,744
-%
Feb 14, 2024
Royal Bank of Canada
reduced
-11.11
-
-
-%
Feb 14, 2024
VANGUARD GROUP INC
added
0.68
-134,458
771,117
-%
Feb 14, 2024
TWO SIGMA SECURITIES, LLC
new
-
20,602
20,602
-%
Feb 14, 2024
Western Standard LLC
added
20.09
36,960
2,397,240
1.60%
Feb 14, 2024
Newtyn Management, LLC
reduced
-10.23
-145,156
457,844
0.09%

1–10 of 30

Are Funds Buying or Selling ABIO?

Are funds buying ABIO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ABIO
No. of Funds

Unveiling ARCA biopharma Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 07, 2024
bml investment partners, l.p.
4.9%
706,930
SC 13G/A
Sep 11, 2023
western standard llc
-
0
SC 13G
Feb 08, 2023
bml investment partners, l.p.
5.95%
858,256
SC 13G/A
Jul 08, 2022
funicular funds, lp
17.91%
2,580,452
SC 13D/A
Jun 21, 2022
funicular fund, lp
17.91%
2,580,452
SC 13D/A
May 27, 2022
ma-weaver jacob
17.91%
2,580,452
SC 13D/A
May 11, 2022
funicular fund, lp
16.64%
2,397,281
SC 13D/A
Apr 14, 2022
funicular fund, lp
15.06%
2,171,100
SC 13D/A
Apr 04, 2022
funicular fund, lp
13.50%
1,944,993
SC 13D/A
Mar 28, 2022
funicular fund, lp
6.49%
935,035
SC 13D

Recent SEC filings of ARCA biopharma Inc

View All Filings
Date Filed Form Type Document
Feb 07, 2024
SC 13G/A
Major Ownership Report
Feb 06, 2024
8-K
Current Report
Feb 01, 2024
10-K
Annual Report
Feb 01, 2024
8-K
Current Report
Jan 31, 2024
4
Insider Trading
Jan 31, 2024
4
Insider Trading
Jan 31, 2024
4
Insider Trading
Jan 31, 2024
4
Insider Trading
Jan 31, 2024
4
Insider Trading
Jan 31, 2024
4
Insider Trading

Peers (Alternatives to ARCA biopharma Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
36.3B
6.8B
-16.59% -47.80%
-7.7
5.3
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.2B
1.8B
-23.99% -31.71%
-43.66
10.51
76.23% 61.08%
16.4B
2.4B
-4.89% -18.90%
98.05
6.79
15.42% 18.43%
13.3B
3.7B
-7.62% -26.87%
22.19
3.59
8.87% 75.42%
MID-CAP
7.7B
396.6M
-2.06% 34.31%
-14.57
19.42
425.83% 18.94%
6.3B
-
-3.85% 226.12%
-10.06
60.35
54.84% -25.61%
4.5B
240.7M
-19.08% -10.99%
-15.05
18.56
-1.03% -92.09%
4.0B
726.4M
-12.60% 32.37%
-64.55
5.45
40.45% 71.62%
3.9B
270.6M
8.92% 47.81%
-16.3
14.41
440.80% -27.84%
SMALL-CAP
2.0B
398.2M
-3.38% -9.50%
28.08
5.03
85.90% -14.05%
752.9M
983.7M
-9.17% -57.89%
-1.38
0.77
-50.36% 17.16%
217.0M
4.9M
-14.18% -58.18%
-1.32
44.39
-57.57% 50.48%
154.8M
881.7K
289.54% 381.25%
-3.26
112.79
-77.61% -13.74%
4.3M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

ARCA biopharma Inc News

Latest updates
Defense World16 Feb 202406:30 am
Yahoo Finance01 Feb 202408:00 am

ARCA biopharma Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-2.3%501,000513,000493,000433,500374,000222,00072,00038,0004,0004,0003,0002,0001,0001,0002,00024,00036,00050,00048,00038,00038,000
Operating Expenses-17.9%1,590,0001,937,0001,973,0001,796,0001,548,0002,552,0003,219,0003,277,0005,680,0004,716,0004,837,0004,102,0005,126,0001,990,0001,310,0001,340,0001,278,0001,247,0001,508,0001,781,0001,527,000
  S&GA Expenses-4.5%1,543,0001,615,0001,719,0001,406,0001,487,0001,528,0001,734,0001,098,0001,739,0001,278,0001,260,0001,226,0001,922,000939,000938,000975,000894,000900,0001,068,0001,119,000902,000
  R&D Expenses-85.4%47,000322,000254,000390,00061,0001,024,0001,485,0002,179,0003,941,0003,438,0003,577,0002,876,0003,204,0001,051,000372,000365,000384,000347,000440,000662,000625,000
EBITDA Margin16.4%-9.86-11.79-14.66-19.38-28.58-37.87-56.08-108-1,484-972-1,389-1,621---------
Interest Expenses--------------2,0003,0004,000-1,0003,0003,000-
Income Taxes----------------9,000--16,000-42,000-27,000-82,000-
Earnings Before Taxes----------5,676,000-4,712,000-4,834,000--5,125,000-1,991,000-1,311,000-1,320,000-1,242,000-1,198,000-1,463,000-1,746,000-1,489,000
EBT Margin16.4%-9.87-11.81-14.68-19.41-28.63-37.92-56.17-108-1,486-974-1,392-1,624---------
Net Income23.5%-1,089,000-1,424,000-1,480,000-1,346,000-1,174,000-2,333,000-3,147,000-3,272,000-5,676,000-4,712,000-4,834,000-4,100,000-5,125,000-1,991,000-1,302,000-1,320,000-1,226,000-1,156,000-1,436,000-1,664,000-1,489,000
Net Income Margin17.7%-2.73-3.31-4.81-8.04-14.71-28.32-48.86-103-1,486-1,877-2,292-2,086---------
Free Cashflow36.7%-1,056,000-1,669,000-694,000-1,595,000-1,494,000-2,498,000-2,622,000-4,300,000-4,954,000-4,884,000-3,736,000-5,231,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-3.4%38.0039.0041.0042.0043.0045.0048.0051.0055.0060.0065.0069.0050.0052.0012.007.009.0010.0010.009.007.00
  Current Assets-3.3%38.0039.0041.0042.0043.0045.0048.0051.0054.0060.0065.0069.0050.0052.0012.007.008.0010.0010.009.007.00
    Cash Equivalents-2.7%37.0038.0040.0041.0042.0044.0046.0049.0053.0058.0063.0067.0049.0051.0011.007.008.0010.0010.008.007.00
  Net PPE-23.1%0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
Liabilities-30.8%1.001.002.002.001.002.003.003.004.004.004.003.004.003.002.002.001.001.001.001.001.00
  Current Liabilities-35.8%1.001.002.001.001.002.003.003.003.003.004.003.003.002.001.001.001.001.001.001.001.00
Shareholder's Equity-2.5%37.0038.0039.0041.0042.0043.0045.0048.0051.0057.0061.0066.0047.0050.0010.006.008.009.009.007.006.00
  Retained Earnings-0.6%-188-187-186-184-183-182-179-176-173-167-163-158-154-149-147-145-144-143-142-140-138
  Additional Paid-In Capital0.1%226226225225225225225225225224224224201199157152152152151148145
Shares Outstanding0.6%15.0014.0014.0014.0014.0014.0014.0014.0014.0014.0013.0012.00---------
Float-------29.00---50.00---15.00---11.00--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations36.7%-1,056-1,669-694-1,595-1,494-2,498-2,622-4,298-4,947-4,870-3,720-5,225-2,995-2,002-1,042-1,686-1,158-887-1,190-1,566-1,343
  Share Based Compensation-8.4%14115418720412097.0017216711910413314118.005.004.0016.0027.0029.0045.0050.0058.00
Cashflow From Investing---------2.00-7.00-14.00-16.00-6.00-13.00--3.00-3.00-2.00----
Cashflow From Financing------------23,09398442,056---1225683,1502,964-105

ABIO Income Statement

2023-12-31
STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Costs and expenses:  
General and administrative$ 6,283$ 5,847
Research and development (related party - $(91) and $432 as of the years ended December 31, 2023 and 2022, respectively)1,0134,749
Total costs and expenses7,29610,596
Loss from operations(7,296)(10,596)
Interest and other income1,957675
Other loss (5)
Net loss$ (5,339)$ (9,926)
Net loss per share:  
Basic$ (0.37)$ (0.69)
Diluted$ (0.37)$ (0.69)
Weighted average shares outstanding:  
Basic14,415,87714,410,143
Diluted14,415,87714,410,143

ABIO Balance Sheet

2023-12-31
BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 37,431$ 42,445
Other current assets161254
Total current assets37,59242,699
Right-of-use asset - operating247343
Property and equipment, net1025
Other assets1218
Total assets37,86143,085
Current liabilities:  
Accounts payable362334
Accrued compensation and employee benefits100173
Accrued expenses and other liabilities (related party - $0 and $216 at December 31, 2023 and 2022, respectively)175625
Total current liabilities6371,132
Operating lease liability, net of current portion204280
Total liabilities8411,412
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.001 par value; 5 million shares authorized; no shares issued or outstanding at December 31, 2023 and 2022
Common stock, $0.001 par value; 100 million shares authorized at December 31, 2023 and 2022; 14,501,143 and 14,410,143 shares issued and outstanding at December 31, 2023 and 2022, respectively1414
Additional paid-in capital225,747225,061
Accumulated deficit(188,741)(183,402)
Total stockholders’ equity37,02041,673
Total liabilities and stockholders’ equity$ 37,861$ 43,085
ABIO
ARCA biopharma, Inc., a clinical development stage biopharmaceutical company, engages in the development and commercialization of genetically targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. It is also developing Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. The company was founded in 2004 and is headquartered in Westminster, Colorado.
 CEO
 WEBSITEwww.arcabio.com
 EMPLOYEES5

ARCA biopharma Inc Frequently Asked Questions


What is the ticker symbol for ARCA biopharma Inc? What does ABIO stand for in stocks?

ABIO is the stock ticker symbol of ARCA biopharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ARCA biopharma Inc (ABIO)?

As of Fri Mar 01 2024, market cap of ARCA biopharma Inc is 24.22 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABIO stock?

You can check ABIO's fair value in chart for subscribers.

What is the fair value of ABIO stock?

You can check ABIO's fair value in chart for subscribers. The fair value of ARCA biopharma Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ARCA biopharma Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ABIO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ARCA biopharma Inc a good stock to buy?

The fair value guage provides a quick view whether ABIO is over valued or under valued. Whether ARCA biopharma Inc is cheap or expensive depends on the assumptions which impact ARCA biopharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABIO.

What is ARCA biopharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Mar 01 2024, ABIO's PE ratio (Price to Earnings) is -4.54 and Price to Sales (PS) ratio is 12.37. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABIO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ARCA biopharma Inc's stock?

In the past 10 years, ARCA biopharma Inc has provided -0.388 (multiply by 100 for percentage) rate of return.